On this page
What should a clinical drug interaction report explain?
Identify each drug’s role, the interaction question, actual administration and sampling, exposure comparisons and uncertainty. Explain whether the conducted regimen tested the intended mechanism. Keep the conclusion within the studied conditions and distinguish the observed result from any proposed clinical management or extrapolation.
Before you begin
Human PK studies evaluating external factors, including clinical drug interactions. Dedicated food-effect BA reports and in-vitro interaction experiments need their specific placement considered.
What you will prepare: A reproducible clinical comparison with clear drug roles, tested conditions and evidence-supported interpretation.
Identify the external factor and each drug’s role
State what external influence the study evaluates: a concomitant drug, smoking, alcohol, dietary context or another factor. For a drug interaction, identify the substrate and precipitant roles and the hypothesized mechanism. Do not call the investigational drug the “victim” or “perpetrator” without defining which exposure or pathway is under assessment.
Collect the protocol, prior mechanistic evidence, dosing and administration schedules, concomitant medication records, bioanalytical reports and analysis outputs. For a dedicated food-effect BA study, consider the specific 5.3.1.1 instructions rather than routing by the word “food” alone. If the primary objective or interacting products are unclear, defer placement and interpretation.
Explain how the regimen tested the proposed mechanism
Describe each treatment condition and its timing so a reviewer can distinguish drug alone from coadministration. Explain regimen selection, sampling, evaluability and analysis in light of the proposed mechanism and the drugs' disposition. Report observed administration departures and whether they compromise the intended interaction assessment.
Present relevant PK parameters, comparisons and uncertainty for the analyzed populations, with PD or safety observations where collected. Account for enrolled participants and reasons data are excluded or unavailable. M12 section V addresses interpretation of clinical DDI results; use the applicable scientific framework rather than declaring any nonsignificant difference proof of no interaction.
Keep “no interaction” inside the tested conditions
Fictional exercise: a negative interaction result was obtained before the intended enzyme-induction regimen was fully delivered. The reviewer should inspect actual administration, mechanism and exposure evidence, then determine whether the test answered the planned question. Repeating the protocol schedule in the methods cannot conceal the different conduct.
Limit the conclusion to the tested drugs, doses and timing, and explain any justified extrapolation separately. Reconcile the report with the in-vitro evidence and clinical pharmacology summary; disagreement needs interpretation, not deletion of one result. Any proposed clinical management advice requires the broader evidence and responsible review, not an automatic recommendation from this checklist.
Compare the intended interaction challenge with actual conduct
Use a regimen check to connect the clinical conduct narrative to the PK interpretation.
| Comparison element | Record | Question before concluding |
|---|---|---|
| Drug roles | Exposure being assessed and interacting agent | Which direction of interaction was evaluated? |
| Administration | Actual doses, sequence and timing | Was the intended interaction condition achieved? |
| Sampling | Analyte and evaluable intervals | Does the result address the planned exposure comparison? |
| Interpretation | Estimate, uncertainty and no-effect boundary rationale | What clinical meaning is supported? |
| Extension | Other proposed drugs, regimens or populations | What additional evidence supports extrapolation? |
Review exercise: an interacting agent was stopped early, but the draft repeats the planned coadministration schedule and concludes there is no relevant effect. Correct the conduct account first, then obtain the clinical pharmacology assessment of what the actual comparison establishes. The result should not be interpreted as if the missing treatment occurred.
Reconcile relevant in-vitro hepatic evidence and the clinical pharmacology summary. A disagreement may reflect different conditions or uncertainty and deserves an explanation, not selective reporting.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a nonsignificant PK difference establish no clinically relevant interaction?
Not by itself. Interpret the estimated change and uncertainty using appropriate no-effect boundaries and the substrate drug’s clinical context. M12 links interpretation to the clinical meaning of exposure changes; a statistical significance label alone does not complete that assessment.
Is a dedicated food-effect BA report always an extrinsic-factor report?
No. M4E provides specific placement instructions for food-effect BA studies at 5.3.1.1. Read the actual primary objective and the relevant family instructions before routing the report. The word food alone does not establish the most appropriate location.
Can one negative DDI study establish no interaction with every drug in a class?
Do not make that extension automatically. State the tested agents, mechanism, doses and timing and identify the evidence supporting any broader inference. The clinical interpretation should preserve uncertainty and distinguish the actual study finding from an extrapolation to other drugs or conditions.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
FDA M4E(R2): The CTD: Efficacy ↗July 2017, Revision 1, final. Module 5, printed pp.56–64. Organization guidance, not a list of studies required for every application. Reopened September 22, 2026.
Guidance
FDA M12: Drug Interaction Studies ↗August 2024 final. Section V on clinical DDI reporting; appendices on in-vitro enzyme and transporter evaluations. Reopened September 22, 2026.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 5.3.3.4. A heading identifies placement, not mandatory applicability.